Business Segment Information (Tables)
|
9 Months Ended |
Apr. 30, 2026 |
|---|
| Business Segment Information [Abstract] |
|
| Schedule of Operating Results for the Business Segments |
Operating results for the business segments of
the Company are as follows:
| (in thousands) | |
Healthcare | | |
Infusion
Technology | | |
Real Estate | | |
Total | |
| Three Months Ended April 30, 2026 | |
| | |
| | |
| | |
| |
| Product revenue | |
$ | 89 | | |
$ | — | | |
$ | — | | |
| 89 | |
| Rental – Third Party | |
| — | | |
| — | | |
| 60 | | |
| 60 | |
| Rental – Related Party | |
| — | | |
| — | | |
| 30 | | |
| 30 | |
| | |
| | | |
| | | |
| | | |
| | |
| COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Cost of product revenue | |
| (8 | ) | |
| — | | |
| — | | |
| (8 | ) |
| General and administrative | |
| (2,079 | ) | |
| (7 | ) | |
| (54 | ) | |
| (2,140 | ) |
| Research and development | |
| (4,852 | ) | |
| (1 | ) | |
| — | | |
| (4,853 | ) |
| Depreciation and amortization | |
| (29 | ) | |
| — | | |
| (19 | ) | |
| (48 | ) |
| (Loss) income from operations | |
$ | (6,879 | ) | |
$ | (8 | ) | |
$ | 17 | | |
$ | (6,870 | ) |
| (in thousands) | |
Healthcare | | |
Infusion
Technology | | |
Real Estate | | |
Total | |
| Nine Months Ended April 30, 2026 | |
| | |
| | |
| | |
| |
| Product revenue | |
$ | 368 | | |
$ | — | | |
$ | — | | |
$ | 368 | |
| Rental – Third Party | |
| — | | |
| — | | |
| 173 | | |
| 173 | |
| Rental – Related Party | |
| — | | |
| — | | |
| 89 | | |
| 89 | |
| | |
| | | |
| | | |
| | | |
| | |
| COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Cost of product revenue | |
| (29 | ) | |
| — | | |
| — | | |
| (29 | ) |
| General and administrative | |
| (7,074 | ) | |
| (36 | ) | |
| (150 | ) | |
| (7,260 | ) |
| Research and development | |
| (16,855 | ) | |
| (11 | ) | |
| — | | |
| (16,866 | ) |
| Depreciation and amortization | |
| (98 | ) | |
| — | | |
| (55 | ) | |
| (153 | ) |
| (Loss) income from operations | |
$ | (23,688 | ) | |
$ | (47 | ) | |
$ | 57 | | |
$ | (23,678 | ) |
| (in thousands) | |
Healthcare | | |
Infusion
Technology | | |
Real Estate | | |
Total | |
| Three Months Ended April 30, 2025 | |
| | |
| | |
| | |
| |
| Infusion technology revenue | |
$ | — | | |
$ | 42 | | |
$ | — | | |
$ | 42 | |
| Product revenue | |
| 243 | | |
| — | | |
| — | | |
| 243 | |
| Rental – Third Party | |
| — | | |
| — | | |
| 49 | | |
| 49 | |
| Rental – Related Party | |
| — | | |
| — | | |
| 28 | | |
| 28 | |
| | |
| | | |
| | | |
| | | |
| | |
| COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Cost of Infusion Technology revenue | |
| — | | |
| (31 | ) | |
| — | | |
| (31 | ) |
| Cost of product revenue | |
| (9 | ) | |
| — | | |
| — | | |
| (9 | ) |
| General and administrative | |
| (3,102 | ) | |
| (37 | ) | |
| (31 | ) | |
| (3,170 | ) |
| Research and development | |
| (3,003 | ) | |
| — | | |
| — | | |
| (3,003 | ) |
| Depreciation and amortization | |
| (13 | ) | |
| (34 | ) | |
| (15 | ) | |
| (62 | ) |
| (Loss) income from operations | |
$ | (5,884 | ) | |
$ | (60 | ) | |
$ | 31 | | |
$ | (5,913 | ) |
| (in thousands) | |
Healthcare | | |
Infusion
Technology | | |
Real Estate | | |
Total | |
| Nine Months Ended April 30, 2025 | |
| | |
| | |
| | |
| |
| Product revenue | |
$ | 243 | | |
$ | — | | |
$ | — | | |
| 243 | |
| Infusion technology revenue | |
| — | | |
| 93 | | |
| — | | |
| 93 | |
| Rental – Third Party | |
| — | | |
| — | | |
| 147 | | |
| 147 | |
| Rental – Related Party | |
| — | | |
| — | | |
| 84 | | |
| 84 | |
| | |
| | | |
| | | |
| | | |
| | |
| COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Cost of Infusion Technology revenue | |
| — | | |
| (106 | ) | |
| — | | |
| (106 | ) |
| Cost of product revenue | |
| (9 | ) | |
| — | | |
| — | | |
| (9 | ) |
| General and administrative | |
| (7,794 | ) | |
| (292 | ) | |
| (198 | ) | |
| (8,284 | ) |
| Research and development | |
| (5,021 | ) | |
| (255 | ) | |
| — | | |
| (5,276 | ) |
| Depreciation and amortization | |
| (15 | ) | |
| (177 | ) | |
| (46 | ) | |
| (238 | ) |
| Loss on impairment of goodwill | |
| — | | |
| (3,050 | ) | |
| — | | |
| (3,050 | ) |
| Loss from operations | |
$ | (12,596 | ) | |
$ | (3,787 | ) | |
$ | (13 | ) | |
$ | (16,396 | ) |
|
| Schedule of Reconciliation of Operations by Reportable Segment |
A reconciliation between loss from operations
by reportable segment to consolidated net loss before income taxes for the three months ended April 30, 2026 and 2025, is as follows:
| | |
April 30,
2026 | | |
April 30,
2025 | |
| (Loss) income from operations by segment | |
| | |
| |
| Healthcare | |
$ | (6,879 | ) | |
$ | (5,884 | ) |
| Infusion Technology | |
| (8 | ) | |
| (60 | ) |
| Real Estate | |
| 17 | | |
| 31 | |
| Total | |
| (6,870 | ) | |
| (5,913 | ) |
| | |
| | | |
| | |
| Reconciliation to loss before income taxes: | |
| | | |
| | |
| Interest income | |
| 286 | | |
| 472 | |
| Unrealized loss on investment - Cyclo | |
| — | | |
| (1,393 | ) |
| Unrealized gain on convertible notes receivable, due from Cyclo | |
| — | | |
| 383 | |
| Interest expense | |
| (6 | ) | |
| (165 | ) |
| Gain on settlement of accounts payable and convertible notes payable | |
| 3,723 | | |
| — | |
| Other income (loss), net | |
| (25 | ) | |
| 154 | |
| Loss before income taxes | |
$ | (2,892 | ) | |
$ | (6,462 | ) |
A reconciliation between loss from operations
by reportable segment to consolidated net loss before income taxes for the nine months ended April 30, 2026 and 2025, is as follows:
| | |
April 30,
2026 | | |
April 30,
2025 | |
| (Loss) income from operations by segment | |
| | |
| |
| Healthcare | |
$ | (23,688 | ) | |
$ | (12,596 | ) |
| Infusion Technology | |
| (47 | ) | |
| (3,787 | ) |
| Real Estate | |
| 57 | | |
| (13 | ) |
| Total | |
| (23,678 | ) | |
| (16,396 | ) |
| | |
| | | |
| | |
| Reconciliation to loss before income taxes: | |
| | | |
| | |
| Interest income | |
| 1,023 | | |
| 1,529 | |
| Realized gain on available-for-sale securities | |
| — | | |
| 178 | |
| Unrealized loss on investment - Cyclo | |
| — | | |
| (5,144 | ) |
| Unrealized loss on convertible notes receivable, due from Cyclo | |
| — | | |
| (719 | ) |
| Interest expense | |
| (327 | ) | |
| (490 | ) |
| Gain on settlement of accounts payable and convertible notes payable | |
| 3,958 | | |
| — | |
| Other income, net | |
| 54 | | |
| 74 | |
| Loss before income taxes | |
$ | (18,970 | ) | |
$ | (20,968 | ) |
|
| Schedule of Net Property, Plant and Equipment |
Net property, plant and equipment and total assets
summarized by geographic area are as follows:
| (in thousands) | |
United States | | |
Israel | | |
Total | |
| April 30, 2026 | |
| | |
| | |
| |
| Property, plant and equipment, net | |
$ | 359 | | |
$ | 1,165 | | |
$ | 1,524 | |
| Total assets | |
| 89,526 | | |
| 2,464 | | |
| 91,990 | |
| July 31, 2025 | |
| | | |
| | | |
| | |
| Property, plant and equipment, net | |
| 321 | | |
| 1,275 | | |
| 1,596 | |
| Total assets | |
| 111,954 | | |
| 2,155 | | |
| 114,109 | |
|